228 related articles for article (PubMed ID: 25992285)
1. Cancer-associated muscle weakness: What's bone got to do with it?
Waning DL; Guise TA
Bonekey Rep; 2015; 4():691. PubMed ID: 25992285
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid improves bone quality and muscle function in a high bone turnover state.
Trivedi T; Manaa M; John S; Reiken S; Murthy S; Pagnotti GM; Dole NS; She Y; Suresh S; Hain BA; Regan J; Ofer R; Wright L; Robling A; Cao X; Alliston T; Marks AR; Waning DL; Mohammad KS; Guise TA
bioRxiv; 2023 Jun; ():. PubMed ID: 37333318
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
4. Excess TGF-β mediates muscle weakness associated with bone metastases in mice.
Waning DL; Mohammad KS; Reiken S; Xie W; Andersson DC; John S; Chiechi A; Wright LE; Umanskaya A; Niewolna M; Trivedi T; Charkhzarrin S; Khatiwada P; Wronska A; Haynes A; Benassi MS; Witzmann FA; Zhen G; Wang X; Cao X; Roodman GD; Marks AR; Guise TA
Nat Med; 2015 Nov; 21(11):1262-1271. PubMed ID: 26457758
[TBL] [Abstract][Full Text] [Related]
5. Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.
Regan JN; Mikesell C; Reiken S; Xu H; Marks AR; Mohammad KS; Guise TA; Waning DL
Front Endocrinol (Lausanne); 2017; 8():358. PubMed ID: 29312148
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.
Hesse E; Schröder S; Brandt D; Pamperin J; Saito H; Taipaleenmäki H
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30965315
[TBL] [Abstract][Full Text] [Related]
7. The Role of TGFβ in Bone-Muscle Crosstalk.
Regan JN; Trivedi T; Guise TA; Waning DL
Curr Osteoporos Rep; 2017 Feb; 15(1):18-23. PubMed ID: 28161871
[TBL] [Abstract][Full Text] [Related]
8. Cancer- and Chemotherapy-Induced Musculoskeletal Degradation.
Sturgeon KM; Mathis KM; Rogers CJ; Schmitz KH; Waning DL
JBMR Plus; 2019 Mar; 3(3):e10187. PubMed ID: 30918923
[TBL] [Abstract][Full Text] [Related]
9. Tumor-bone cellular interactions in skeletal metastases.
Chirgwin JM; Mohammad KS; Guise TA
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):308-18. PubMed ID: 15615499
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of breast cancer metastases to bone.
Guise TA; Kozlow WM; Heras-Herzig A; Padalecki SS; Yin JJ; Chirgwin JM
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S46-53. PubMed ID: 15807924
[TBL] [Abstract][Full Text] [Related]
11. PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases.
Yang Y; Wang B
Int J Endocrinol; 2018; 2018():7120979. PubMed ID: 30151009
[TBL] [Abstract][Full Text] [Related]
12. Immune regulation of bone metastasis.
Capietto AH; Faccio R
Bonekey Rep; 2014; 3():600. PubMed ID: 25512853
[TBL] [Abstract][Full Text] [Related]
13. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.
Chirgwin JM; Guise TA
J Cell Biochem; 2007 Dec; 102(6):1333-42. PubMed ID: 17907152
[TBL] [Abstract][Full Text] [Related]
14. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta in osteolytic breast cancer bone metastases.
Guise TA; Chirgwin JM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
18. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin diminishes advanced bone cancer pain.
Luger NM; Honore P; Sabino MA; Schwei MJ; Rogers SD; Mach DB; Clohisy DR; Mantyh PW
Cancer Res; 2001 May; 61(10):4038-47. PubMed ID: 11358823
[TBL] [Abstract][Full Text] [Related]
20. In vitro mimics of bone remodeling and the vicious cycle of cancer in bone.
Krishnan V; Vogler EA; Sosnoski DM; Mastro AM
J Cell Physiol; 2014 Apr; 229(4):453-62. PubMed ID: 24022654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
